Why did Inspire Medical Systems (INSP) stock move recently?

On 7/22/2026, Inspire Medical Systems moved -4.0% — INSP declined with the broader market and healthcare sector on no clear company-specific catalyst; the July 22 8-K on a director retirement is routine and unlikely to drive the move. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Inspire Medical Systems (INSP) overvalued or fairly valued?

MarketChacha shows Inspire Medical Systems's valuation in context — a forward P/E of about 41.1, a price-to-book of about 2.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Inspire Medical Systems's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.53×) from reported figures — education, not a rating.

What is Inspire Medical Systems's revenue?

Inspire Medical Systems reported revenue of $912.0M for FY2025, with net profit of $145.4M, per official filings.

What is the share price of Inspire Medical Systems (INSP)?

Inspire Medical Systems last traded at $63.19 (+1.7% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Inspire Medical Systems

INSP · NYSE · Healthcare · United States

Snapshot

TickerINSP

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees1,333

HeadquartersGolden Valley, United States

Websitewww.inspiresleep.com

Filings tracked19

About Inspire Medical Systems

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Who owns it

Insiders1.2%
Institutions98.8%
Public & other0.0%

382 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.16.39%
Wellington Management Group, LLP8.24%
Vanguard Portfolio Management LLC7.23%
Soleus Capital Management, L.P.6.68%
AQR Capital Management, LLC6.42%
UBS Group AG5.69%
Shaw D.E. & Co., Inc.5.09%
Nomura Holdings Inc.4.74%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.53×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend-3.4% → 15.9%

Margin has expanded by about 19.3 points — the business is getting more profitable.

Return on equity18.6%

Latest ROE of 18.6% — capital is generating a healthy return.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $244.4M · EPS 0.91

Est. earnings growth -44.7%

Next fiscal year

Rev $887.6M · EPS 1.54

Est. earnings growth +23.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$912.0M

Net margin

15.9%

ROE

18.6%

Revenue CAGR (2y)

+20.8%

EPS (FY2025)

4.89

Net profit (FY2025)

$145.4M

Ask MarketChacha about INSP

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 22, 2026
INSP declined with the broader market and healthcare sector on no clear company-specific catalyst; the July 22 8-K on a director retirement is routine and unlikely to drive the move.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$912.0M	$145.4M	4.89	15.9%	18.6%
FY2024	$802.8M	$53.5M	1.75	6.7%	7.8%
FY2023	$624.8M	$-21.2M	-0.72	-3.4%	-3.7%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$200.6M	$314,000	0.01	0.2%
2026Q1	$204.6M	$-11.3M	-0.39	-5.5%
2025Q3	$224.5M	$9.9M	0.34	4.4%
2025Q2	$217.1M	$-3.6M	-0.12	-1.7%
2025Q1	$201.3M	$3.0M	0.10	1.5%
2024Q3	$203.2M	$18.5M	0.60	9.1%
2024Q2	$195.9M	$9.8M	0.32	5.0%
2024Q1	$164.0M	$-10.0M	-0.34	-6.1%
2023Q3	$153.3M	$-8.5M	-0.29	-5.6%
2023Q2	$151.1M	$-12.0M	-0.41	-7.9%
2023Q1	$127.9M	$-15.4M	-0.53	-12.1%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/3/2026material
10-Q filing
SEC8/3/2026
8-K — Executive/director change
SEC7/24/2026material
8-K — Executive/director change, Exhibits
SEC7/22/2026material
8-K — Reg FD disclosure, Exhibits
SEC6/26/2026material
8-K — Executive/director change, Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/5/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/4/2026material
10-Q filing
SEC5/4/2026
10-K filing
SEC2/13/2026
8-K — Results of operations, Bylaw/charter change, Reg FD disclosure, Exhibits
SEC2/11/2026material
8-K — Results of operations, Executive/director change, Reg FD disclosure, Exhibits
SEC1/12/2026material

2025

8-K — Other events
SEC11/17/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/3/2025material
10-Q filing
SEC11/3/2025
8-K — Reg FD disclosure, Exhibits
SEC10/10/2025material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC8/26/2025material
8-K — Other events, Exhibits
SEC8/11/2025material
8-K — Results of operations, Executive/director change, Reg FD disclosure, Exhibits
SEC8/4/2025material
10-Q filing
SEC8/4/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.